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Abstract: Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from 
blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be 
important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a
relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has 
been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive 
agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic 
studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might 
be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.  
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INTRODUCTION 
  The purpose of treating patients with increased cardiovascular 
risk is to reduce that risk. It is well established that blood pressure 
lowering per se substantially reduces cardiovascular risk. Both the 
renin-angiotensin system (RAS) and the sympathetic nervous 
system (SNS) play an important role in the pathogenesis of various 
forms of hypertension. Independent of their effect on blood 
pressure, these systems also contribute to the pathophysiology of 
both structural and functional cardiovascular abnormalities. As a 
consequence, counteracting the mechanisms involved in the patho-
genesis of cardiovascular organ damage is also important, indepen-
dent of any direct blood pressure lowering effect.  
  There is conclusive evidence that the RAS and SNS systems do 
not operate independently, but that there are multiple interactions 
on different levels of the cardiovascular system. It is well estab-
lished that angiotensin converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) reduce the effects of 
angiotensin II Fig. (1). These therapies also appear to have 
sympatholytic properties, which may be particularly important in 
determining the efficacy of these agents in reducing cardiovascular 
risk, since there is abundant evidence that sympathetic hyperactivity 
is associated with poor clinical outcome.  
  In this brief review, we outline the interactions between the 
RAS and the SNS. Because eprosartan is a relatively new ARB, 
chemically distinct from other ARBs, it seems appropriate to 
summarize available evidence of eprosartan as sympatholytic agent, 
and briefly review data on experience with this compound in 
various hypertensive populations.  
ANGIOTENSIN – SYMPATHETIC INTERACTIONS 
  RAS/SNS interactions appear bi-directional and occur at 
different sites in the chain of events leading to angiotensin II and 
noradrenaline release, the two major transmitters of these two 
systems [1]. There is clear experimental evidence that the sympa-
thetic outflow to the kidneys regulates renin release. Electrical 
stimulation of the renal nerves, as well as of certain central nervous 
system areas, causes an increase in renin release. There is a large 
body of evidence in various experimental settings indicating that 
angiotensin II facilitates the sympathetic nervous system on 
different levels. It has been shown that intra-cerebral infusion of 
angiotensin II causes a pressor response associated with an increase 
in vascular resistance. On a peripheral level, angiotensin II also 
elicits stimulatory action, because it stimulates neural transmission 
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across sympathetic ganglia, potentiates at the presynaptic level 
noradrenaline release from sympathetic nerve terminals and ampli-
fies the alpha-adrenoceptor mediated vasoconstrictor response to 
endogenous noradrenaline Fig (2). Further, angiotensin II exerts 
inhibitory effects on baroreflex modulation of the heart rate and 
sympathetic drive. The idea that AngII directly stimulates centrally 
originated sympathetic outflow in humans was tested in an elegant 
study. Intravenous infusion of AngII raised blood pressure and 
suppressed muscle sympathetic nerve activity. But during simul-
taneously infusion of nitroprusside to control blood pressure rise, 
MSNA increased. An identical experiment with phenylephrine 
infusion showed no effect on MSNA [2].  
  Various pathological conditions are associated with hyper-
activity of both the RAS and SNS systems, including hypertension, 
heart failure, kidney disease, hypertension associated with obesity 
and obstructive sleep apnea syndrome amongst others. In the 
majority of these conditions both the RAS and the SNS are 
activated.Becausecirculatingrenin is (almost) exclusively produced 
by the kidneys, it is logical to question how the kidneys might 
contribute to the increased activities of the two pressor systems in 
the above-mentioned conditions. The precise role of a local i.e. 
tissue RAS is much more difficult to quantify and evaluate.  
  Experimental studies have shown several pathophysiological 
mechanisms through which the diseased kidneys can be involved. 
Inappropriate renin secretion in relation to the state of sodium-
volume balance has long been recognized. In humans, intravenous 
infusion of angiotensin II stimulates central sympathetic outflow.  
  Renal ischemia can lead to sympathetic activation. During renal 
ischemia, adenosine is released and adenosine evokes an increase in 
afferent renal nerve traffic, as can be shown during adenosine 
infusion in the renal artery of uninephrectomized dogs. Even a 
small injury in one kidney caused by intrarenal injection of phenol, 
which does not affect glomerular filtration rate, leads to hyper-
tensionin association with an increased central sympathetic activity. 
In these animal models renal denervation results in a reduction or 
total prevention of hypertension. Additionally, in the phenol 
hypertension model nephrectomy of the injured kidney several 
weeks after the induction of renal damage results in normalisation 
of blood pressure. Thus kidney injury in experimental conditions 
can lead to sympathetic hyperactivity and hypertension and this 
hyperactivity is associated with activation of renal afferent nerves. 
The signal from the diseased kidneys travels via the afferent renal 
nerves to the central nervous system Fig. (3).  
  Some forms of essential hypertension, hypertension associated 
with chronic kidney disease, renovascular hypertension, heart 
failure, and obesity/metabolic syndrome are all associated with both 
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the RAS are particularly effective in reducing sympathetic activity 
when the RAS is activated. The apparent marked parallelism in the 
activities of these two systems may be interpreted as indicating a 
cause and effect relation or a common origin, i.e. kidney ischemia 
Fig.(3).Giventheimportance of sympathetic activity in determining 
cardiovascular morbidity and mortality, it is important to quantity 
the ability of agents that affect the RAS to reduce sympathetic 
activity.  
EPROSARTAN: EFFECTS ON THE RENIN-ANGIOTENSIN 
AND THE SYMPATHETIC NERVOUS SYSTEM. 
  Eprosartan is chemically-distinct from the other ARBs in its 
class [3, 4]. It is the only ARB that belongs to the non-biphenyl, 
non-tetrazole class of compounds and does not contain a biphenyl, 
tetrazole moiety Fig. (4). The antagonistic properties of eprosartan 
on the angiotensin II receptor type 1 (AT1) have been extensively 
documented [5]. Unlike most other ARBs, which show noncom-
petitive kinetics, eprosartan is a pure competitive antagonist. Based 
on the absence of a direct comparison of eprosartan with other 
ARBs, the clinical relevance of the difference in chemical structure 
and kinetics has to be judged as unclear.  
  Angiotensin II may stimulate the SNS on various levels Fig (2).
Consequently, ARBs can block this stimulatory effect of angio-
tensin II at these different levels. The effects of eprosartan on 
sympathetic activity have been studied in experimental conditions. 
Eprosartan induces dual blockade of angiotensin II receptors both 
pre- and post-synaptically Fig. (2). Importantly, it has been shown 
that eprosartan crosses the blood-brain barrier, which pro-bably 
contributes to its antihypertensive efficacy [6]. The question 
whether ARBs have sympatholytic effects is addressed in experi-
mental studies. For instance, Balt et al. [7] compared in the pithed 
rat model the efficacy of valsartan, candesartan, embusartan, telmi-
sartan, eprosartan, losartan and irbesartan on pre- and postjuncional 
AngII receptors. Eprosartan appeared the most effective agent with 
respect to prejunctional effects. Ohlstein et al. [8] studied activation 
of sympathetic outflow through spinal cord stimulation in the pithed 
rat. Eprosartan inhibited sympathetic outflow – but not losartan, 
valsartan or irbesartan. This difference might mean that eprosartan 
is a more effective antagonist of prejunctional AngII receptors that 
augment noradrenaline release. Shetty and Delgrande [9] found that 
eprosartan inhibited neuronal noradrenaline release in a rat atria 
model by AngII enhancement of electrical stimulation, which might 
Fig. (1). Schematic representation of the renin-angiotensin system and the sites of action of angiotensin converting enzyme (ACE) inhibitors and angiotensin II 
receptor blockers.
Fig. (2). Schematic representation of the central nervous system (CNS) and a neuro-effector junction. Levels are indicated where angiotensin II (Ang II) can 
enhance (+) sympathetic activity and where angiotensin II receptor blocker (Ang II blocker) can reduce (-) sympathetic activity.
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be interpreted as an effect on prejunctional AngII receptors. 
Criscione et al. [10] found valsartan had no effect on stimulation 
induced activation of the sympathetic nervous system in pithed rats. 
Nap and colleagues [11] showed in isolated rabbit thoraric aorta 
that the AngII enhanced electrical field stimulation evoked sympa-
thetic transmission was more effectively inhibited by candesartan 
than eprosartan. It is important to emphasize that studies are 
difficult to compare because protocol, experimental design, dosage 
and methodology vary substantially between studies. However, they 
seem to indicate that ARBs have a clear action on both pre- and 
postjunctional AngII receptors, and that there might be differences 
in this respect between the various compounds. Importantly, also in 
humans, there is some indication of different efficacy. For instance, 
in hypertensive patients Arosio et al. [12] reported that 15 days of 
eprosartan (600 mg od) blocks noradrenergic effects during stress 
more effectively than valsartan (160 mg od). These data suggest 
that in hypertensive humans there could be a difference between 
ARBs in their efficacy to block the noradrenergic system and any 
such difference might be meaningful [13]. 
EPROSARTAN IN CLINICAL PRACTICE 
Essential Hypertension 
  The clinical efficacy of eprosartan has been established in a 
number of trials, both against placebo and other compounds. This 
agent clearly has a 24-hour blood pressure lowering effect during 
chronic treatment at the standard dose of 600 mg/day [14]. Epro-
sartan showed similar or greater antihypertensive effect compared 
with enalapril. For instance, both agents reduced blood pressure, 
but the response rate at 12 weeks for eprosartan (200-300 mg bid) 
was greater than with enalapril (5-20 mg od) (70% vs 63%, p<0.05) 
[15]. In severely hypertensive patients, eprosartan (200-400 mg bid) 
more effectively reduced systolic blood pressure with no difference 
in diastolic blood pressure reduction as compared to enalapril (10-
40 mg od) after 8 weeks [16]. In a study of mainly elderly patients 
once daily 600-800 mg eprosartan or once daily enalapril 5-20 mg 
for 12 weeks reduced blood pressure to a similar extent, with 
similar proportions of patients in both treatment arms achieving a 
response [17]. In yet another study in essential hypertensives, once 
daily eprosartan (400-800 mg) resulted in significantly greater 
decrease in blood pressure than placebo [18]. 
  A recent study in essential hypertensive patients, assessing both 
brachial and central blood pressures (pulse wave analysis, Sphygmo 
Cor System) presented similar reductions during eprosartan (600 
mg od) and atenolol (50 mg od) in peripheral blood pressure after 6 
weeks. Both agents reduced central systolic pressure, albeit epro-
sartan more so than atenolol, but only eprosartan reduced wave 
reflections.Centralpressures more closely relate to clinical outcome 
than peripheral pressures, suggesting an advantage of eprosartan 
over atenolol [19]. These findings confirm earlier studies indicating 
differential effects of various antihypertensive agents on central 
pressures (for instance the CAFE Study [20, 21]) and suggest a 
mechanism to support the meta-analyses that have challenged the 
recommendation to use a beta-blocker in uncomplicated hyperten-
sion [22-24]. However, superiority can only be really proven by 
direct comparison in properly designed studies with relevant 
clinical endpoints.  
Fig. (3). Schematic representation of the kidney involvement in the pathogenesis of sympathetic hyperactivity. 
Already minimal kidney damage, not necessarily affecting kidney function, results in area(s) of ischemia. Increased plasma levels of angiotensin II and/or 
increased afferent renal nerve activity stimulates the central nervous system to increase central sympathetic outflow, which results in sodium retention and 
vasoconstriction which are meant to restore kidney perfusion.
Fig. (4). Eprosartan (left) is a non-biphenyl, non-tetrazole angiotensin II receptor blocker (ARB), other ARBs are biphenyl tetrazoles (right).256    Cardiovascular & Hematological Agents in Medicinal Chemistry, 2008, Vol. 6, No. 4 Blankestijn and Rupp 
  In patients with mild hypertension and type 2 diabetes once 
daily eprosartan (600 mg od) and telmisartan (40 mg od) were 
equally effective in reducing blood pressure during a 12 months 
study [25]. Obesity is often associated with a raised sympathetic 
activity leading not only to hypertension, but also insulin resistance 
[26]. Essential hypertension is a heterogenous condition. Some 
forms are associated with increased sympathetic activity whilst 
others are not. Krum et al. showed that in mild to moderate 
essential hypertension ARB treatment (eprosartan 600 mg and 
losartan 50 mg, both od during 4 weeks) did not affect muscle 
sympathetic nerve activity, which is the centrally originated 
postganglionic sympathetic activity [27].  
Renal Disease 
  There is clear evidence that chronic renal disease is often 
characterised by the presence of sympathetic hyperactivity and that 
sympathetic activity is associated with poor cardiovascular out-
comes in chronic renal failure patients [28-30]. It is important to 
realize that already minor kidney injury, not necessarily affecting 
kidneyfunction, may cause sympathetic hyperactivity. This increase 
in sympathetic activity is thought to both initiate and sustain the 
elevated blood pressure that contributes to organ damage and 
adverse cardiovascular events [31]. It may also affect the pro-
gression of renal failure [30].  
  Current evidence suggests there is no accumulation of 
eprosartan at the recommended dose of 600 mg, regardless of renal 
function. Chronic treatment (> 6 weeks) with enalapril (20 mg od) 
and losartan (100 mg od) significantly reduced but do not 
normalized muscle sympathetic nerve activity in patients with 
hypertensive chronic renal failure [32, 33]. Eprosartan (600 mg od) 
reduced muscle sympathetic nerve activity, blood pressure and also 
heart rate (all p<0.05), suggesting that not only the sympathetic 
activity towards the resistance vasculature but also the cardiac 
sympathetic activity is decreased with eprosartan. Combining epro-
sartan with the centrally-acting sympatholytic agent moxonidine 
normalised both blood pressure and muscle sympathetic nerve 
activity in hypertensive normovolemic patients with chronic renal 
failure [32]. Studies directly comparing effects on muscle sympa-
thetic nerve activity, which is considered one of the gold standards 
for quantifying sympathetic activity in humans, of eprosartan and 
other agents in disease states with high sympathetic activity are 
presently not available.  
  Experimental studies with eprosartan suggest that it might have 
a benefit in the prevention or delay of renal damage in hypertensive 
patients with renal impairment [34, 35]. Frank et al. [36] showed 
that eprosartan (600 mg od for 7 days) preserves renal circulation 
during states of neurohumoral activation, suggesting an important 
renoprotective effect of this compound. Osei et al. [37] noted an 
enhancement of the renal vasodilator effect of eprosartan (600 mg) 
during hyperglycemia consistent with activation of the intrarenal 
RAS. 
The Elderly 
  Isolated systolic hypertension is the most common form of 
hypertension in the elderly [38, 39]. Eprosartan has been shown to 
be an effective agent in the elderly. In a double-blind study versus 
placebo in 283 elderly patients with a mean age of 70 years 
eprosartan once-daily at doses of 600-1200mg during 3 months 
produced a significant reduction in systolic blood pressure (epro-
sartan vs. placebo: 16 and 8 mmHg, p<0.0001) [40]. For patients 
who did not respond to eprosartan alone, the addition of 
hydrochlorothiazide provided additive reduction in systolic blood 
pressure (eprosartan vs. placebo: 22 and 14 mmHg, p<0.002). In a 
26-week comparative study with enalapril (5 – 20 mg od), 
eprosartan at doses of 200-300mg twice daily, alone or in combi-
nation with hydrochlorothiazide once daily, was shown to be safe 
and effective in hypertensive patients over 65 years of age [41]. 
Antihypertensive efficacy of eprosartan and enalapril did not differ. 
In an equal percentage of patients, the diuretic was added.  
  In the ETAPA (Estudio de la Efectividad del Tratamiento 
antihipertensivo sobre la Presion de Pulso en adultos) study from 
Spain involving approximately 4,000 hypertensive patients (mean 
age 67 y), eprosartan (600 mg) alone (87%) or in combination with 
a diuretic decreased systolic, diastolic and mean (resp. 26 mmHg, 
13 mmHg and 17 mmHg, all p<0.01) blood pressure in hyper-
tensive patients and was associated with a reduction in pulse 
pressure / mean blood pressure ratio (62 => 58%, p<0.05) [42]. 
Also in the Robles et al. study, eprosartan (600 mg od for 16 
weeks) in the primary care setting was well tolerated and effective 
in over 600 patients (mean age 63 y) in reducing blood pressure 
(systolic, diastolic and mean blood pressure resp: 26, 13 and 17 
mmHg, all p<0.001) as well as pulse pressure (13 mmHg, p<0.001). 
Also the pulse pressure / mean arterial pressure ratio decreased (62 
=> 59%, p< 0.001) [43]. 
Other High Risk Populations 
  The MOSES study (MOrbidity and mortality after Stroke, 
Eprosartan compared with nitrendipe for Secondary prevention) is a 
large, prospective, randomised outcome study comparing the 
addition of 600 mg eprosartan or 10 mg nitrendipine to existing 
therapy in patients with a history of proven stroke or transient 
ischaemic attack [44]. Background therapy did not differ between 
the two groups. In MOSES, 1405 patients were followed up for 2.5 
years with eprosartan or nitrendipine. The primary outcomes were 
total mortality and cardiovascular and cerebrovascular disease and 
the secondary outcomes were mental status, neurological status and 
ambulatory blood pressure. Blood pressure did not differ between 
the treatment arms. There was a significant reduction of 21% in the 
primary endpoint (all-cause mortality and the number of cardio-
vascular and cerebrovascular events, including all recurrent events) 
and of 25% (p=0.026) in the recurrence of stroke, and of 30% in 
first time cardiovascular events. This important study indicates that 
meaningful prevention, beyond an effect on blood pressure, can be 
obtained in a high risk population. Although there has been some 
concern on the reliability and relevance of the study [45], it extends 
the existing information on the effects of ARBs in high risk 
patients. Some, but not all, other studies with ARBs suggest that 
these agents especially reduce strokes. For instance in the LIFE 
study in hypertensive patients with left ventricular hypertrophy 
losartan based therapy reduced stroke better than beta-blocker 
based therapy [46]. In contrast, in the VALUE study, valsartan was 
nonsignificantly worse than amlodipine in stroke prevention, but 
post hoc analyses suggested that this may have been attributable to 
less effective blood pressure control during valsartan during the 
first 6 months [47]. In ACCESS, candesartan (or placebo) was 
given after 7 days after onset of stroke. Neurological outcome after 
1 year in the ARB treated group was better than in the placebo 
group [48]. The mechanism of this possible beneficial effect may 
lie in the selective blocking by ARBs of the deleterious effects 
mediated through the AT1 receptor, whereas the effects on the AT2 
receptor are unaffected or even enhanced [49]. AT2 receptor seem 
to mediate beneficial effects on endothelium through decreased 
coagulation and inflammation and these receptors also protect brain 
tissue from ischemia in experimental models [50, 51].  
Ongoing Studies 
  Although different in terms of structure and mode of action, 
eprosartan has, to date, been seen as one of many sartans. Ongoing 
studies are now focusing in other areas where reduction of 
sympathetic activity might be expected to show benefit.  
  The STARLET study (Stress-induced Hypertension at the 
Workplace) will examine the prevalence of ‘job-strain’ hyperten-
sion and cardiovascular outcomes. Job-strain hypertension is 
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and/or 8mm Hg systolic blood pressure between work and weekend 
mean daytime ambulatory blood pressure. First results show that 
eprosartan effectively reduced blood pressure [51]. 
  The OSCAR study will be a long-term, open-label, study 
examining the effects of eprosartan-based therapy (600 mg od) on 
systolic blood pressure and cognitive function. Results from this 
study are also awaited with interest [52, 53].  
CONCLUSION 
  The goal of antihypertensive treatment is not only to lower 
blood pressure but also to reduce risk of cardiovascular morbidity 
and mortality. It is important not only to quantify the blood pressure 
lowering effect of antihypertensive compounds, but also to assess 
their ability to counteract mechanisms involved in the pathogenesis 
of cardiovascular morbidity and mortality, such as the hyper-
activities of the renin-angiotensin system and the sympathetic 
nervous system. Eprosartan is an effective antihypertensive agent 
and clearly belongs to the class of ARBs, reversing effects of the 
renin and the sympathetic system. Experimental and pharmaco-
kinetic studies have shown differences with the other ARBs. Since 
direct comparison of effects of eprosartan and other ARBs on 
meaningful clinical endpoints is not available, the clinical relevance 
of these differences has to be judged as unclear.  
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